AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Santhera Pharmaceuticals Holding AG
Video analysis: SANN.SW
All videosNo video analysis for this stock yet. Request one from our team.
News: SANN.SW
Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®
Data support AGAMREE's potential use as a treatment across a broad range of chronic inflammatory rare diseases Pratteln, Switzerland, July 1, 2026 - Santhera Pharmaceuticals (SIX: SANN) today notes topline results from a two-part Phase 1 clinical study of AGAMREE conducted by its North American licensing partner, Catalyst Pharmaceuticals, Inc.
Santhera gibt Topline-Ergebnisse der klinischen Phase-1-Studie von Catalyst Pharmaceuticals zu AGAMREE® bekannt
Die Daten untermauern das Potenzial von AGAMREE als Therapie für ein breites Spektrum chronisch-entzündlicher seltener Erkrankungen Pratteln, Schweiz, 1. Juli 2026 - Santhera Pharmaceuticals (SIX: SANN) gibt heute die Topline-Ergebnisse einer zweiteiligen klinischen Phase-1-Studie zu AGAMREE bekannt, die von seinem nordamerikanischen Lizenzpartner Catalyst Pharmaceuticals, Inc.
Similar companies
-
Molecular Partners AG
MOLN.SW
·
Swiss Exchange
Compare
-
Ascom Holding AG
ASCN.SW
·
Swiss Exchange
Compare
-
Addex Therapeutics Ltd
ADXN.SW
·
Swiss Exchange
Compare
-
EvoNext Holdings S.A.
EVE.SW
·
Swiss Exchange
Compare
-
Newron Pharmaceuticals S.p.A.
NWRN.SW
·
Swiss Exchange
Compare
-
SHL Telemedicine Ltd.
SHLTN.SW
·
Swiss Exchange
Compare